Skip to content
1887

Abstract

No longitudinal molecular epidemiology of parechovirus A3 (PeV-A3) over a decade is available and PeV-A3-associated myalgia/myositis has been reported only in Japan. Thus, we aimed to clarify the longitudinal molecular epidemiology of PeV-A3 with a major focus on the strains detected from PeV-A3-associated myalgia/myositis cases. We performed sequence and phylogenetic analysis for the VP1 region of PeV-A3 strains in Yamagata, Japan, between 2003 and 2016. The phylogenetic analysis indicated that PeV-A3 strains caused PeV-A3-associated myalgia/myositis as well as a variety of infectious diseases, ranging from mild to severe, in subjects ranging from neonates to adults, irrespective of genetic cluster or variations. PeV-A3 strains are causative agents of a variety of human diseases, irrespective of their genetic cluster. Furthermore, we consider that PeV-A3-associated myalgia/myositis may occur, not only in Japan, but also in other countries, as closely related PeV-A3 strains have been circulating around the world.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000894
2018-12-17
2025-07-10
Loading full text...

Full text loading...

References

  1. Romero JR, Modlin JF. Human parechoviruses. In Blaser MJ. (editor) Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th ed. Philadelphia: Saunders Elsvier; 2015 pp. 2091–2094
    [Google Scholar]
  2. Pallansch MA, Oberste MS, Whitton JL. Enteroviruses: polioviruses, coxsackieviruses echoviruses, and newer enteroviruses. In Knipe DM, Howley PM. (editors) Fields’s Virology, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013 pp. 490–530
    [Google Scholar]
  3. Ito M, Yamashita T, Tsuzuki H, Takeda N, Sakae K. Isolation and identification of a novel human parechovirus. J Gen Virol 2004; 85:391–398 [View Article][PubMed]
    [Google Scholar]
  4. Harvala H, Simmonds P. Human parechoviruses: biology, epidemiology and clinical significance. J Clin Virol 2009; 45:1–9 [View Article][PubMed]
    [Google Scholar]
  5. Esposito S, Rahamat-Langendoen J, Ascolese B, Senatore L, Castellazzi L et al. Pediatric parechovirus infections. J Clin Virol 2014; 60:84–89 [View Article][PubMed]
    [Google Scholar]
  6. Ito M, Yamashita T, Tsuzuki H, Kabashima Y, Hasegawa A et al. Detection of human parechoviruses from clinical stool samples in Aichi, Japan. J Clin Microbiol 2010; 48:2683–2688 [View Article][PubMed]
    [Google Scholar]
  7. van der Sanden S, de Bruin E, Vennema H, Swanink C, Koopmans M et al. Prevalence of human parechovirus in the Netherlands in 2000 to 2007. J Clin Microbiol 2008; 46:2884–2889 [View Article][PubMed]
    [Google Scholar]
  8. Harvala H, Robertson I, Chieochansin T, Mcwilliam Leitch EC, Templeton K et al. Specific association of human parechovirus type 3 with sepsis and fever in young infants, as identified by direct typing of cerebrospinal fluid samples. J Infect Dis 2009; 199:1753–1760 [View Article][PubMed]
    [Google Scholar]
  9. Aizawa Y, Suzuki Y, Watanabe K, Oishi T, Saitoh A. Clinical utility of serum samples for human parechovirus type 3 infection in neonates and young infants: The 2014 epidemic in Japan. J Infect 2016; 72:223–232 [View Article][PubMed]
    [Google Scholar]
  10. Schuffenecker I, Javouhey E, Gillet Y, Kugener B, Billaud G et al. Human parechovirus infections, Lyon, France, 2008-10: evidence for severe cases. J Clin Virol 2012; 54:337–341 [View Article][PubMed]
    [Google Scholar]
  11. Nelson TM, Vuillermin P, Hodge J, Druce J, Williams DT et al. An outbreak of severe infections among Australian infants caused by a novel recombinant strain of human parechovirus type 3. Sci Rep 2017; 7:44423 [View Article][PubMed]
    [Google Scholar]
  12. Sharp J, Harrison CJ, Puckett K, Selvaraju SB, Penaranda S et al. Characteristics of young infants in whom human parechovirus, enterovirus or neither were detected in cerebrospinal fluid during sepsis evaluations. Pediatr Infect Dis J 2013; 32:213–216 [View Article][PubMed]
    [Google Scholar]
  13. Pham NT, Trinh QD, Khamrin P, Maneekarn N, Shimizu H et al. Diversity of human parechoviruses isolated from stool samples collected from Thai children with acute gastroenteritis. J Clin Microbiol 2010; 48:115–119 [View Article][PubMed]
    [Google Scholar]
  14. Huang YP, Hsieh JY, Wu HS, Yang JY. Molecular and epidemiological study of human parechovirus infections in Taiwan, 2007-2012. J Microbiol Immunol Infect 2016; 49:321–328 [View Article][PubMed]
    [Google Scholar]
  15. Tanaka S, Aoki Y, Matoba Y, Yahagi K, Itagaki T et al. Seroepidemiology of human parechovirus types 1, 3, and 6 in Yamagata, Japan, in 2014. Microbiol Immunol 2016; 60:854–858 [View Article][PubMed]
    [Google Scholar]
  16. Mizuta K, Kuroda M, Kurimura M, Yahata Y, Sekizuka T et al. Aoki Y, Ikeda T, Abiko C, Noda M, Kimura H, Mizutani T, Kato T, Kawanami T, Ahiko T. Epidemic myalgia in adults associated with human parechovirus type 3 infection, Yamagata, Japan, 2008. Emerg Infect Dis 2012; 18:1787–1793
    [Google Scholar]
  17. Mizuta K, Yamakawa T, Nagasawa H, Itagaki T, Katsushima F et al. Epidemic myalgia associated with human parechovirus type 3 infection among adults occurs during an outbreak among children: findings from Yamagata, Japan, in 2011. J Clin Virol 2013; 58:188–193 [View Article][PubMed]
    [Google Scholar]
  18. Mizuta K, Yamakawa T, Kurokawa K, Chikaoka S, Shimizu Y et al. Epidemic myalgia and myositis associated with human parechovirus type 3 infections occur not only in adults but also in children: findings in Yamagata, Japan, 2014. Epidemiol Infect 2016; 144:1286–1290 [View Article][PubMed]
    [Google Scholar]
  19. Yamakawa T, Mizuta K, Kurokawa K, Nagasawa H, Yamada T et al. Clinical characteristics of 17 adult patients with epidemic myalgia associated with human parechovirus type 3 infection. Rinsho Shinkeigaku 2017; 57:485–491 [View Article][PubMed]
    [Google Scholar]
  20. Kurimura M, Mizuta K, Yamakawa T, Kato T. HPeV3-associated myalgia/myositis: Epidemic myalgia as an emerging infectious disease. Neurol Med 2017; 86:307–314
    [Google Scholar]
  21. Yamamoto SP, Kaida A, Naito T, Hosaka T, Miyazato Y et al. Human parechovirus infections and child myositis cases associated with genotype 3 in Osaka City, Japan, 2014. J Med Microbiol 2015; 64:1415–1424 [View Article][PubMed]
    [Google Scholar]
  22. Shinomoto M, Kawasaki T, Sugahara T, Nakata K, Kotani T et al. Yoshitake H, Yuasa K, Saeki M, Fujiwara Y. First report of human parechovirus type 3 infection in a pregnant woman. Int J Infect Dis 2017; 59:22–24
    [Google Scholar]
  23. Tanaka S, Kunishi Y, Ota M, Ono A, Kanno N et al. Kurakami Y, Yanagibashi T, Matsubayashi M, Hao Y, Iwabuchi K, Oshita F, Yoshie K, Kato Y. Severe human parechovirus type 3 infection in adults associated with gastroenteritis in their children. Infect Dis 2017; 49:772–774
    [Google Scholar]
  24. Matsuuchi S, Abe A, Daitsu T, Maeda S, Shimizu Y. Clinical characteristics of human parechovirus 3 infection in seven neonates and infants. J Pediatr Infect Dis Immunol 2018; 30:19–25
    [Google Scholar]
  25. National Institute of Infectious Diseases and Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare Weekly detection of human parechovirus type 3 in 2013 and 2014, Japan. Infectious Agents Surveillance Report http://www.nih.go.jp/niid/images/iasr/arc/ot/2014/data2014.84j.pdf Accessed 25th February 2016
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.000894
Loading
/content/journal/jmm/10.1099/jmm.0.000894
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error